Synapse - Nivetha Ganesan

Results (54)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases

Meeting Abstract

Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
Blood (2024)

Fulltext@MSK | Save

A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign

Meeting Abstract

Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study

Meeting Abstract

Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
Blood (2024)

Fulltext@MSK | Save

Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis

Meeting Abstract

Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Meeting Abstract

Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
Blood (2024)

Fulltext@MSK | Save

Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
Blood (2024)

Fulltext@MSK | Save

Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma - International, multi-center real-world experience

Meeting Abstract

Luttwak, E.; Kambhampati, S.; Drill, E.; Ganesan, N.; Hofstetter, L.; Gurion, R.; Aumann, S.; Haran, A.; Geva, M.; Panossian, M.; more...
Blood (2024)

Fulltext@MSK | Save